Bayer acquired KaNDy Therapeutics for $425M upfront plus up to $450M in success-based milestones plus triple-digit million sales milestones. Lead asset NT-814 (now elinzanetant) is a dual NK-1/NK-3 receptor antagonist for menopausal vasomotor symptoms.
Key facts
AnnouncedSep 16, 2019
Deal value$875M
Deal typeAcquisition/Merger
Therapeutic areaVasomotor symptoms (menopausal hot flashes)
IndicationsVasomotor symptoms (menopausal hot flashes)
Key assetsNT-814 (elinzanetant)
MechanismDual neurokinin-1 and neurokinin-3 receptor antagonist